[HTML][HTML] Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional …

RI Scahill, P Zeun, K Osborne-Crowley… - The Lancet …, 2020 - thelancet.com
Background Disease-modifying treatments are in development for Huntington's disease;
crucial to their success is to identify a timepoint in a patient's life when there is a measurable …

[HTML][HTML] Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult …

EB Johnson, CS Parker, RI Scahill, S Gregory… - …, 2021 - thelancet.com
Abstract Background Pathological processes in Huntington's disease (HD) begin many
years prior to symptom onset. Recently we demonstrated that in a premanifest cohort …

Neurofilament light-associated connectivity in young-adult Huntington's disease is related to neuronal genes

P McColgan, S Gregory, P Zeun, A Zarkali, EB Johnson… - Brain, 2022 - academic.oup.com
Upregulation of functional network connectivity in the presence of structural degeneration is
seen in the premanifest stages of Huntington's disease (preHD) 10–15 years from clinical …

Validation of remote collection and quantification of blood Neurofilament light in neurological diseases.

A Coleman, A Touzé, M Farag, M Pengo, MJ Murphy… - medRxiv, 2023 - medrxiv.org
Promising blood-based biomarkers of neuropathology have emerged with potential for
therapeutic development and disease monitoring. However, these tools will require …

F59 Huntington's disease young adult study (HD-YAS)

P Zeun, J Lowe, K Osborne-Crowley, C O'Callaghan… - 2018 - jnnp.bmj.com
HD-YAS will study a cohort of young adult HD Gene Expansion Carriers (HDGEC) decades
before expected symptom onset to characterize the very earliest signs of disease-related …

D06 Influencing Huntington's disease monitoring and therapeutic development with remote quantification of blood neurofilament light protein

LM Byrne, JL Schultz, S Field, K Fayer, Y Hassan… - 2022 - jnnp.bmj.com
Background Neurofilament light protein (NfL) has emerged as the leading biomarker
candidate for disease progression and early detection of adult-onset Huntington's Disease …

F05 Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis

R Scahill, P Zeun, K Osborne-Crowley, E Johnson… - 2021 - jnnp.bmj.com
Background Disease-modifying treatments are in development for Huntington's disease
(HD); crucial to their success in delaying or preventing onset is to identify a timepoint when …

Longitudinal follow up of the Huntington's Disease Young Adult Study (HD-YAS 2.0)

F Mena, M Michael, F Kate, H Nichola, S Rachael… - 2023 - jnnp.bmj.com
Background Huntington's disease (HD) is an autosomal dominant neurodegenerative
condition. The Young Adult Study (HD-YAS) characterised the earliest pathological …

Exploring the early neuropathology of Huntington's disease using 7T MRI and MEG in HD-YAS 2.0

M Michael, F Mena, N Mitsuko, F Kate, MC Peter… - 2023 - jnnp.bmj.com
Background The Huntington's Disease Young Adult Study (HD-YAS) provided a detailed
analysis of early premanifest Huntington's disease (preHD) participants along with age and …

[CITATION][C] Detection of Early Neurodegeneration with Fluid Biomarkers in the HD Young Adult Study

P Zeun, RI Scahill… - …, 2020 - SPRINGER ONE NEW YORK …